(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Vote in favor of your Number one Kind of Gems - 2Comet MAPS faces a make-or-break moment as it dives toward the sun on April 4 — could it shine in the daytime sky?
- 3Parents search for children missing since a volcanic eruption in Colombia 40 years ago
- 47 Moves toward a Sound and Dynamic Way of life
- 5Top 15 Supportable Design Brands Coming out on top
- FOX8 Meteorologist Charles Ewing makes his 2025-26 winter weather predictions!
- First SpaceX booster for upgraded Starship fails during test in Texas
- Fuel Price Spike Drives Surge in Used EV Sales in Europe
- Tech for Learning: Online Courses and Instructive Apparatuses
- Report: Russian military pressuring students to work as drone pilots
- Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- Disability rights activist and author Alice Wong dies at 51
- Becoming Familiar with an Unknown dialect: My Language Learning Excursion
